UNSPSC 51373413: Bromodiphenhydramine/codeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373413 Bromodiphenhydramine/codeine is a Commodity code that in recent state and local procurement covers pharmaceutical products and related healthcare supplies delivered to correctional and community health facilities. The Washington State Department of Corrections' RFQ RFQQK13020 (response due October 7, 2026) solicits parenteral products, services, and equipment — including parenteral nutrition solutions, intravenous solutions, and controlled substances for incarcerated individuals — with delivery requirements of 24 hours for TPN/PPN bags and 8 hours for other parenteral products across eight correctional facilities in three regions. The issuing bodies sourcing under this code include state departments of corrections and county health agencies, both of which require vendors to demonstrate clinical and logistical competence, maintain substantial insurance coverage, and comply with state business licensing and background-clearance requirements. Set-aside programs vary by issuer: Washington DOC explicitly encourages participation from small businesses (25% goal), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%), with a documented subcontractor inclusion plan requirement, while other jurisdictions may not specify similar designations.

Activity under the code appears concentrated in the Pacific Northwest and Southeast. Washington State has generated the most recent solicitation, with the DOC's multiregional parenteral-products contract representing a substantial, ongoing procurement spanning November 2026 through at least June 2030 with extension options and fixed pricing for the initial two-year term. Seminole County, Florida also appears in the record, though its recent opportunity (IFB60459723LAS, posted June 30, 2026) targets naloxone and drug deactivation systems rather than bromodiphenhydramine/codeine specifically, suggesting either a tagging mismatch or a broader code application in county health purchasing. Vendors pursuing these opportunities must clear Washington State Patrol NCIC background checks where required, maintain commercial general liability ($1–2 million), professional liability ($2 million), and cyber liability ($2 million) coverage, and accept firm pricing commitments for 150 days post-award.